Multiple mechanisms of cancer immune resistance have been proposed over the last few decades: tumor heterogeneity, tumor antigen and major histocompatibility complex (MHC) modulation, anti-apoptotic pathways, checkpoint inhibitory ligands, immunosuppressive cell subsets, immunosuppressive factors in the tumor microenvironment (TME), and T cell activation-induced cell death (AICD). Here, HLA-C is linked to neoplasm.